Helen Louise Collins
CHIEF MEDICAL OFFICER; Director · 12 filings · Latest: Sep 17, 2026
Enliven Therapeutics, Inc.
Kura Oncology, Inc.
| Ticker | Owner | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Filing |
|---|---|---|---|---|---|---|---|---|---|
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 10, 2026 | Option Exercise | $2.48 | 10,129 | $25.1K | 35,129 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 9, 2026 | Sale | $30.02 | 29,871 | $896.8K | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Mar 9, 2026 | Option Exercise | $2.48 | 29,871 | $74.1K | 54,871 | |
ELVN | Collins Helen Louise | — | Mar 9, 2026 | Proposed Sale | $29.44 | 45,000 | $1.3M | — | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Sale | $26.17 | 45,000 | $1.2M | 25,000 | |
ELVN | Helen Louise Collins | CHIEF MEDICAL OFFICER | Feb 17, 2026 | Option Exercise | $2.48 | 45,000 | $111.6K | 70,000 | |
ELVN | Collins Helen Louise | — | Feb 17, 2026 | Proposed Sale | $26.72 | 45,000 | $1.2M | — | |
ELVN | Collins Helen Louise | — | Oct 18, 2024 | Proposed Sale | $28.02 | 25,000 | $700.5K | — |
← Previous
Page 2 of 2